Natera Partners with TransCode to Accelerate MRD-Guided Colorectal…

Event summary

Natera and TransCode Therapeutics will collaborate on a Phase 2a trial of TTX-MC138 for colorectal cancer (CRC) patients with molecular residual disease (MRD).
The trial will use Natera’s Signatera test to identify MRD-positive patients who have completed curative-intent therapy but show no radiographic evidence of disease.
The study is part of the PRE-I-SPY program, marking its first expansion beyond breast cancer into CRC.
TTX-MC138 targets microRNA-10b, a biomarker linked to metastatic cancers, aiming to address a critical treatment gap for MRD-positive patients.

The big picture

This collaboration underscores the growing importance of MRD-guided strategies in oncology, particularly for high-risk cancer patients with no approved therapies. The partnership leverages Natera’s established MRD testing footprint to streamline clinical development, a trend likely to accelerate as precision medicine becomes more integral to cancer treatment paradigms. The success of this trial could validate a new treatment paradigm focused on early intervention before clinical recurrence.

What we're watching

Trial Efficiency: How the integration of Signatera’s MRD testing will impact the pace and quality of patient enrollment in the Phase 2a trial.
Therapeutic Potential: Whether TTX-MC138 can successfully intervene in the molecular residual disease stage to prevent CRC recurrence.
Market Expansion: The pace at which the PRE-I-SPY program expands into additional cancer indications beyond breast and colorectal cancer.